A prescription-only compound that forces the brain into its deepest sleep, then clears fast. It reliably relieves the sleepiness of a rare sleep disorder, eases widespread chronic pain, and amplifies the night's first growth hormone pulse. The gap between the sleep dose and the dose that suppresses breathing is narrow. Nothing is known about decades of nightly use. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Apnea–hypopnea index | <5 events per hour | Determines whether dosing is safe at all |
| Serum sodium | 138–142 mmol/L | Detects accumulating load from the sodium formulation |
| Home blood pressure (seated, morning average) | <120/80 mmHg | The clinically meaningful consequence of nightly sodium |
| Serum bicarbonate | 24–28 mmol/L | Flags acid-base shift from chronic salt loading |
| eGFR | >90 mL/min/1.73 m² | Kidney reserve for handling the nightly salt load |
| Overnight oxygen saturation nadir | ≥94% | Catches the individual desaturation tail that group averages hide |
| Epworth Sleepiness Scale | 0–5 points | Primary efficacy anchor for daytime function |
| PHQ-9 depression score | 0–4 points | Labelled risk of mood deterioration and suicidal ideation |
| Body weight | Within 2% of personal baseline | Detects the documented weight-loss signal |
| IGF-1 | Age- and sex-adjusted 50th–75th percentile | Tracks whether the growth hormone signal translates downstream |
| Slow-wave sleep duration | No established target; track change from own baseline | The mechanism the intervention is being used for |
Cadence: 1, 4, and 12 weeks during dose escalation, then every 6 months once stable. Sodium, bicarbonate, and kidney function at each stable-phase review; blood pressure monthly on the sodium formulation; mood screening quarterly; overnight breathing study annually or after any 5 kg weight gain.